The standard-of-care backbone for younger patients with AML using the combination of the nucleoside analog cytarabine and an anthracycline has changed little over the last decade, with the exception of adding midostaurin in FLT3-mutated patients, and is only moderately effective in the majority of patients (~40–50% 5-year OS) [42]. This evidence concerns the gene FLT3 and acute myeloid leukemia.